IMPEDIMED

ASX:IPD

QUARTERLY ACTIVITIES REPORT

APPENDIX 4C – Quarter Ended 31 December 2021

31 January 2022

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

THREE KEY MESSAGES

impedimed®

Robust results

- ✓ Robust quarter despite meaningful impact from Omicron variant
- ✓ Record results in Q2 FY'22 for SOZO® SaaS revenue
- ✓ $50.8m cash balance and fully funded to cashflow break-even post capital raising

PREVENT Trial

- ✓ PREVENT Trial peer-reviewed, accepted and pending publication in coming days
- ✓ Met primary end point
- ✓ Statistically significant
- ✓ Showed statistical benefit across all risk factors

Foundation laid for accelerated growth

- ✓ Rapidly expanding our Case Assistance Program (CAP) due to its overwhelming success
- ✓ CAP will be strengthened by PREVENT Trial publication
- ✓ Principal Investigators to submit NCCN application in the coming week
- ✓ Measured expansion of customer facing resources as we accelerate growth

Q2 FY'22 OVERALL BUSINESS RESULTS

impedimed®

TOTAL REVENUE

$0.2m
Legacy Business

$2.4m
SOZO Business

- SaaS Revenue from Core Business
- SaaS Revenue from Clinical Business (AstraZeneca)
- New SOZO contracts signed and device revenue

$2.6m
TOTAL REVENUE
+ 26%
YOY^

$50.8m
CASH ON HAND

$2.6m	$(2.9)m
CASH RECEIPTS	NET OPER. CASH OUTFLOW

^ YOY denotes Year-over-Year change in metric.
^^ QOQ denotes Quarter-over-Quarter change in metric.

All FY'22 revenue and cash flow numbers are unaudited.
All figures are stated in Australian dollars (AUD) unless otherwise notated.

Q2 FY'22 SOZO® BUSINESS PERFORMANCE

$2.2m

SOZO SaaS REVENUE

+ 71%

YOY^

$8.4m

ARR[i]

+ 7%

YOY

$14.3m

CRP[ii]

- 3%

YOY

Decline in CRP due to recognition of AZ revenue

35,000+

PATIENT TESTS

+ 19%

YOY

90%+

SaaS GROSS MARGINS

2%

CHURN RATE[iv]

98% Renewal Rate[v]

^ YOY denotes Year-over-Year change in metric.
i Annual Recurring Revenue (ARR): The amount of revenue reasonably expected to be booked for the next 12-month period based on existing signed contracts, and assuming installation upon sale.
ii Contracted Revenue Pipeline (CRP): Future period revenue amounts related to TCV[iii] that are yet to be reported as recognised revenue.
iii Total Contract Value (TCV): Total value of customer contracts including one-time and recurring revenue.
iv [Churn] / [(Total device placements at beginning of period + Total device placements at end of period) / 2]
v [Total number of end-user customer contracts with expiration dates during the period that were retained] / [Total number of customer contracts with expiration dates during the period]

All FY'22 revenue and cash flow numbers are unaudited.
ARR, CRP and TCV are unaudited, non-AASB financial metrics that do not represent revenue in accordance with Australian Accounting Standards. The values shown for total ARR and CRP are across all lines of business, including the Core Business and Clinical Business.
All figures are stated in Australian dollars (AUD) unless otherwise notated.

Q2 FY'22 ARR AND CRP

impedimed®

Foundation laid for accelerated growth

		LAND ACCOUNTS	EXPAND TESTING	EXPAND PROGRAMS
$8.4m^ ARR[i]	Q2 FY'22 →	24 Units Sold Globally ~60%+ of US units from new accounts	35,000+ Additional Patient Tests Continued COVID-19 impact on testing in quarter	• 36 NCCN/NCI Member Institutions with addition of UT Health San Antonio • Expanded footprint in world-class cancer centres including Memorial Sloan Kettering • Landed/expanded 10 add'l regional cancer centres
$14.3m^ CRP[ii]	TO DATE →	830+ Units Sold to Date in Core Business 410+ Add'l Units in Clinical Business	350,000+ Patient Tests to Date^ 1 billion+ Data Points on file	90%+ SaaS Gross Margins ^^ 90%+ Margins expected on the full $14.3m in CRP

i Annual Recurring Revenue (ARR): The amount of revenue reasonably expected to be booked for the next 12-month period based on existing signed contracts, and assuming installation upon sale.
ii Contracted Revenue Pipeline (CRP): Future period revenue amounts related to TCV[iii] that are yet to be reported as recognised revenue.
iii Total Contract Value (TCV): Total value of customer contracts including one-time and recurring revenue.
^ Patient Tests to Date include tests conducted through 28 January 2022.
^^ Gross Margins are based on the year-to-date value for the six-months ended 31 December 2021.

All FY'22 revenue and cash flow numbers are unaudited.
ARR, CRP and TCV are unaudited, non-AASB financial metrics that do not represent revenue in accordance with Australian Accounting Standards. The values shown are for total ARR and CRP across all lines of business, including the Core Business and Clinical Business.
All figures are stated in Australian dollars (AUD) unless otherwise notated.

Q2 FY'22 CASH FLOW

impedimed®

Business now fully funded to Cash Flow Break-Even

$50.8m CASH ON HAND Q2 FY'22	**$2.6m** Cash Receipts from Customers^	**$(2.9)m** Net Operating Cash Outflow	**$42.5m^^** Gross Proceeds from Placement & SPP
Commentary for upcoming quarter	Cash Receipts to steadily increase in Q3^	Net Operating Cash Outflow to temporarily rise in Q3 before reverting to <$3.0m in Q4	Q3 capital expenditure to increase in line with Capital Raising objectives^^: Advanced Inventory Purchases, SOZO II, EHR Integration, ESRD Clinical Trial

^ Five (5) consecutive quarters of increased Cash Receipts.
^^ In accordance with the Use of Funds from the October 2021 Capital Raise, the Company expects that Net Operating Cash Outflows will increase in Q3 FY'22 prior to coming back down in Q4 FY'22. The increase in cash outflows for Q3 FY'22 include advance inventory purchases; SOZO II and software development costs; Executive short-term incentive payouts that were held over from FY'21 pending the PREVENT publication; and clinical trial costs related to End Stage Renal Disease. Net Operating Cash Outflows for Q3 FY'22 are expected to be in the range of $5.5 million - $6.5 million, with the Net Operating Cash Outflow spend coming back down in Q4 FY'22 to below $3.0 million.

All FY'22 revenue and cash flow numbers are unaudited.
All figures are stated in Australian dollars (AUD) unless otherwise notated.

Q2 FY'22 SOZO REVENUE AND PATIENT TESTS

$10m+
Annual Revenue Run Rate

$2.2m
SOZO SaaS Revenue
+71% YOY
✓ **RECORD QUARTER**

35,000+
Patient Tests
+19% YOY





^The values shown are for SaaS Revenue are across all lines of business, including the Core Business and Clinical Business. The Company began breaking out revenue from the Clinical Business in Q1 FY'21.
^^ Patient Tests to Date include tests conducted through 28 January 2022.

All FY'22 revenue and cash flow numbers are unaudited.
All figures are stated in Australian dollars (AUD) unless otherwise notated.

PREVENT Trial

"The results of this study provide clarity for patients and clinicians regarding breast cancer-related lymphoedema screening and early intervention,"
- Dr. Chirag Shah.^

KEY TO A SIGNIFICANT ACCELERATION OF NEAR-TERM RESULTS

PREVENT Trial peer-reviewed, accepted and pending publication:

- PREVENT Trial results have been peer-reviewed, accepted and are pending publication in *Lymphatic Research and Biology*, a journal dedicated to research on lymphatic biology and pathology from the world's leading biomedical investigators.
- The findings of the manuscript were unchanged from the preprint.
- PREVENT is the largest Level I randomised trial ever to assess subclinical lymphoedema detection.

PREVENT Trial results:

- PREVENT Trial met primary end point and reached statistical significance.
- In patients with early detection using L-Dex, intervention resulted in a 7.9% rate of chronic lymphoedema compared to a 19.2% rate of chronic lymphoedema in patients with early detection using tape measure (p=0.016).
- This represents an absolute reduction of 11.3% and relative reduction of 59%.
- 92% of patients with early detection of cancer-related lymphoedema using L-Dex and intervention did not progress to chronic lymphoedema.
- Results demonstrate that BIS screening should be a standard approach for prospective breast cancer-related lymphoedema (BCRL) surveillance.

^ Dr. Chirag Shah, Director of Breast Radiation Oncology and Director of Clinical Research in the Department of Radiation Oncology at Cleveland Clinic and co-investigator of the PREVENT Trial

Foundation laid for accelerated growth post-PREVENT

DUAL PATH APPROACH TO REIMBURSEMENT

Private Payor Reimbursement:

- PREVENT delivers clear path to reimbursement
- Significant momentum building with IPD's Case Assistance Program:
  - Won 1,723 cases with commercial payors, up from 298 at the time of October capital raising ("Oct 21 CR")
  - 96% of all cases won to date with target payors (97% Oct 21 CR)
  - 1,800+ active cases (1,300+ at Oct 21 CR)
- The case wins are fairly distributed across all major payors
- Conducted first payor advisory board meeting

NCCN Guidelines®:

- Principal Investigators to submit NCCN application in the following week
- Current Guidelines:
  - Early detection is key for optimal management
  - Consider pre-treatment baseline measurements
- Majority of clinicians still using tape measure to comply
- PREVENT removes any ambiguity regarding the comparison of BIS to a tape measure. Statistically and clinically significant evidence that BIS assists in preventing lymphoedema
- BIS L-Dex being specified in NCCN Guidelines would significantly accelerate adoption

Business Updates

BUSINESS UPDATES

Despite COVID-19 and Omicron impacts, the business continues to move positively forward:

- Record levels of disruption across the US due to Omicron during the quarter (most prevalent on US healthcare system).
- Strong results despite this level of disruption.
- Corporate Accounts: commenced a pilot program with a major hospital system and are in discussion for two other pilots with national groups.
- Continued to add and expand our footprint in world-class cancer centers, including Memorial Sloan Kettering and UT Health San Antonio.
- Landed a major oncology group, our first entree into this critical segment.
- Landed or expanded 10 additional regional cancer centres.

Business now fully funded to Cash Flow Break-Even:

- Strong foundation from PREVENT and reimbursement for an acceleration of growth once COVID-19 impacts recede.
- Realigned the sales approach to leverage the success of Case Assistance Program.
- Measured expansion of customer facing resources as we accelerate growth.
- US sales and corporate accounts teams focusing on 3 distinct segments:
  - breast surgeons, oncology groups and Regional & National Cancer Centres
- Expecting accelerating unit sales and rising ASPs over the balance of the calendar year
- Completed a $42.5 million Placement and SPP in October 2021
  - Company now fully funded to break-even

KEY MILESTONES: SUMMARY OF ACHIEVEMENTS IN Q2 FY'22

impedimed®

CORP.

- ☑ Completed a $42.5 million Placement and SPP in October 2021.
- ☑ Colliers Securities, a leading diversified and professional services and investment management company, initiated US coverage of ImpediMed with a Buy rating.
- ☑ Record results in Q2 FY'22 for SOZO® SaaS Revenue, up 71% year-over-year to $2.2 million.

ONCOLOGY

- ☑ PREVENT Trial results peer-reviewed, accepted and pending publication in *Lymphatic Research and Biology* journal.
- ☑ Significant momentum building with IPD's Case Assistance Program for reimbursement.
- ☑ Sales reorganisation, pivoting the Company towards its focus on Corporate Accounts and growth opportunities from the Case Assistance Program within the Oncology market.

HEART FAILURE

- ☑ Established initial protocols for SOZO Heart Failure program at Advocate Health Care's Heart Institute, which is part of AdvocateAurora Health. Advocate is a key heart failure centre for piloting the clinical and commercial applicability of SOZO and reimbursement.
- ☑ AstraZeneca trial extended and expanded, resulting in over 410 SOZO devices being leased across the ongoing AstraZeneca trials. In total, the contracts are expected to generate over $5.0 million in revenue across the trials.

RENAL FAILURE

- ☑ Continued successful deployment of devices for the AstraZeneca trials, both in the US and internationally.
- ☑ Progressed regulatory and commercial strategies for Renal Failure following receipt of FDA Breakthrough Device Designation for a proposed indication in a renal patient population.

KEY MILESTONES: SUMMARY OF FOCUS AREAS FOR Q3 FY'22

impedimed®

ONCOLOGY

- ☐ Principal Investigators to submit NCCN Guidelines® application in the coming week.
- ☐ Continue to expand case assistance program for private payor coverage/payment for L-Dex® testing.
- ☐ Land and expand key cancer centres, medical oncology groups and corporate accounts.
- ☐ Allocate resources to key growth areas based on positive trends developing in installed devices and utilisation.

HEART FAILURE

- ☐ Expand commercial sales of heart failure through additional pilot programs in key heart failure centres.
- ☐ Gather real world data on SOZO and reimbursement through the AdvocateAurora Health heart failure program.
- ☐ Continue to work on obtaining clearance for removal of SOZO contraindications for implantable pacing and cardioverter defibrillator devices.

RENAL FAILURE

- ☐ Principal Investigators and Observational Study to be announced and commenced.
- ☐ Partner with the FDA and Principal Investigators in breakthrough sprint sessions on a clinical evidence plan and trial design for a renal failure interventional trial.
- ☐ Continued deployment of devices for the AstraZeneca trials, both in the US and internationally.

SOZO CASE STUDY: DEACONESS WOMEN'S HOSPITAL – HIGH POINTE

Multidisciplinary Oncology Rehabilitation using SOZO: Real World Experience from High Pointe Therapy

Lorien Appman and Keri Clayborn of Deaconess Women's Hospital – High Pointe Therapy discuss how they have successfully implemented an Oncology Prehabilitation to Rehabilitation Program for lymphedema prevention. They share their expertise on topics such as planning, building strong referral pathways, marketing and optimizing reimbursement. Learn how they are using a multi-disciplinary approach and creative strategies to grow their program and provide patients with best-in-class preventative care.

impedimed®

SOZO Evaluation: ROI

- Evaluate current patient case load
- Calculate return on investment (ROI)

Conservative Estimate

CALCULATIONS

MEASUREMENTS

Payer	Year 1	Year 2	Year 3	TOTAL
Medicare	65	169	273	507
Private Payor	98	254	410	761
TOTAL	163	423	683	1,268

REIMBURSEMENT

Payer	Year 1	Year 2	Year 3	TOTAL
Medicare	$8,255	$21,463	$34,671	$64,389
Private Payor	$0	$0	$0	$0
TOTAL	$8,255	$21,463	$34,671	$64,389

View the full presentation here:

https://youtu.be/2Q9NpxkSjOY

For more on ImpediMed and the LPP:

See the strength of the Lymphedema Prevention Program and Case Assistance Program in action

SOZO Current Utilization

Actual Utilization – Initial Six Months

Average 37 per month once up-and-running

Aug	Sept	Oct	Nov	Dec	Jan
39	32	41	49	30	33

Case Assistance Program:

- Private payer average payment: $212
- 34 cases resolved - $7,208
- 118 cases under review with potential income of $25,000+

IMPEDIMED

Contact Details

Investor Relations Contact:
Mike Bassett, ImpediMed
T : +61 407 431 432
E: mbassett@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit www.impedimed.com.

31 January 2022

ASX ANNOUNCEMENT

QUARTERLY ACTIVITIES REPORT

APPENDIX 4C – Quarter Ended 31 December 2021 (Q2 FY'22)

ImpediMed Limited (ASX.IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health, today released its Appendix 4C – Quarterly Cash Flow report for the period ended 31 December 2021.

Highlights

Quarterly Results

- Total Revenue for Q2 FY'22 of $2.6 million, +26% on the previous corresponding period (pcp).
- Record quarter for SOZO SaaS Revenue for Q2 FY'22 of $2.2 million, +71% pcp.
- Record quarter for cash receipts of $2.6 million.
- AstraZeneca trial extended and expanded with an estimated value of over $500k in additional revenue, resulting in over 410 SOZO devices being leased across the ongoing AstraZeneca trials. In total, the contracts are expected to generate over $5.0 million in revenue across the trials.

Subsequent Events

- PREVENT Trial results have been peer-reviewed, accepted and are pending publication in *Lymphatic Research and Biology*, a journal dedicated to research on lymphatic biology and pathology from the world's leading biomedical investigators.
    - Primary endpoint met.
    - Statistically significant.
    - The findings of the manuscript were unchanged from the preprint.

Revenue Summary:

- Total Revenue for Q2 FY'22 of $2.6 million, +26% pcp (Q2 FY'22: $2.1 million) and flat quarter over quarter.
- SOZO® Revenue for Q2 FY'22 of $2.4 million, +28% pcp (Q2 FY'21: $1.9 million) and -3% quarter over quarter.
- Record quarter for SOZO SaaS Revenue for Q2 FY'22 of $2.2 million, +71% pcp and +4% quarter over quarter.
    - SOZO SaaS Revenue of $1.4 million from Core Business[i].
    - SOZO SaaS Revenue of $0.8 million from Clinical Business[ii].

Cash Flow Summary:

- Cash on hand as at 31 December 2021 of $50.8 million.
- Record quarter for cash receipts from customers of $2.6 million.
- Net operating cash outflows for the quarter of $2.9 million.
- Capital Raising:
    - $35.0 million oversubscribed Placement to new and existing institutional and sophisticated investors.
    - $7.5 million oversubscribed Share Purchase Plan to eligible shareholders.

- Sufficient capital raised to achieve breakeven while still allowing for investment in key growth initiatives including:
    - product enhancement of the SOZO II digital health platform, including weight scales and improved electronics for renal and heart failure;
    - data and software enhancements including corporate account development such as electronic health record integration and heart failure programs; and
    - the development and commercialisation of renal failure application, including end stage renal disease clinical trial and US FDA clearance.
- Related Parties: During the quarter, the Company Directors received a combination of cash remuneration, as well as issued shares as equity-based remuneration in lieu of cash, as described in Item 6 of the Appendix 4C.
- These payments to directors consisted of cash payments of $68,000 as well as $70,000 in Directors' fees accrued and unpaid at 31 December 2021 related to equity-based remuneration.

Operational Summary and Key SaaS Metrics:

- Patient Tests of over 35,000 recorded in Q2 FY'22, +19% pcp.
- Annual Recurring Revenue[iii] of $8.4 million, +7% pcp and -7% quarter over quarter.
    - ARR of $6.7 million from Core Business, +37% pcp.
    - ARR of $1.7 million from Clinical Business.
    - The decline in ARR quarter over quarter was expected, based on the timing of revenue recognition under the AstraZeneca contracts.
- Contracted Revenue Pipeline[iv] of $14.3 million, -3% pcp and -1% quarter over quarter.
    - The decline in CRP was based on the timing of revenue recognition under the AstraZeneca contracts and on the impact of COVID-19 on the timing of signing pending contracts.
- Total Contract Value (TCV[v]) of $1.5 million signed in Q2 FY'22.
- Over 90%+ Gross Margins on SaaS Revenue.
- Churn Rate remains negligible at just 2%.
    - Renewal Rate of 98% on contracts up for renewal during the quarter.
- 24 new SOZO devices sold in Q1, totaling more than 830 SOZO units sold since launch.
    - 36 NCCN/NCI Member Institutions with the addition of the University of Texas Health Science Center at San Antonio.
    - Expanded footprint in world-class cancer centres, including Memorial Sloan Kettering.
    - Landed and expanded 10 additional regional cancer centres.

Subsequent Events

PREVENT Results

- PREVENT Trial results have been peer-reviewed, accepted and are pending publication in *Lymphatic Research and Biology*, a journal dedicated to research on lymphatic biology and pathology from the world's leading biomedical investigators.
    - Primary endpoint met with statistical and clinical significance achieved.
    - The findings of the manuscript were unchanged from the preprint.
- Prevent results released on medRxiv.org. Preprint manuscript can be found at:
    - https://www.medrxiv.org/content/10.1101/2021.10.12.21264773v1
- In patients with early detection using L-Dex, intervention resulted in a 7.9% rate of chronic lymphoedema compared to a 19.2% rate of chronic lymphoedema in patients with early detection using tape measure (p=0.016).
- This represents an absolute reduction of 11.3% and relative reduction of 59%.
- The paper concluded that these statistically significant results demonstrate that bioimpedance spectroscopy (BIS) screening should be a standard approach for prospective breast cancer-related lymphoedema surveillance.

“We continue to drive double-digit growth; despite the ongoing global pandemic, the forward indicators in our business look very positive. We have made substantial progress with reimbursement over the last quarter, which, together with the pending publication of the PREVENT trial manuscript, puts us in a very strong position to execute our business plan throughout 2022,” said Richard Carreon, Managing Director and CEO of ImpediMed.

“With the publication of the PREVENT trial just days away and the momentum in the business, we are indeed at an inflection point. We expect to see both accelerating unit sales and increasing ASPs over the balance of 2022. I want to thank you for your continued support as we look forward to another transformational year,” he continued.

Approved for release by the Managing Director and CEO, Mr Richard Carreon.

Contact Details

Investor Relations Contact:
Mike Bassett, ImpediMed
T : +61 407 431 432
E: mbassett@impedimed.com

About ImpediMed
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

---

[i] The **Core Business** refers to the commercialisation efforts from the Company's core strategic focus areas. To date, this primarily includes revenue from SOZO contracts in the Oncology market.

[ii] The **Clinical Business** refers to revenue generating contracts related to clinical trials. These contracts are often finite in nature, as they relate to clinical trials with specific end dates.

[iii] **Annual Recurring Revenue (ARR):** The amount of revenue reasonably expected to be booked for the next 12-month period based on existing signed contracts, and assuming installation upon sale.

[iv] **Contracted Revenue Pipeline (CRP):** Future period revenue amounts related to TCV that are yet to be reported as recognised revenue.

[v] **Total Contract Value (TCV):** Total value of customer contracts including one-time and recurring revenue.

- *All FY'22 revenue and cash flow numbers are unaudited.*
- *CRP, ARR and TCV are non-IFRS financial metrics that do not represent revenue in accordance with Australian Accounting Standards.*
- *All figures are stated in Australian dollars (AUD) unless otherwise notated.*

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
ImpediMed Limited	
ABN	**Quarter ended ("current quarter")**
65 089 705 144	31 December 2021

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (6 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	2,605	5,069
1.2	Payments for		
	(a) research and development	(149)	(371)
	(b) product manufacturing and operating costs	(522)	(1,200)
	(c) advertising and marketing	(179)	(434)
	(d) leased assets	-	-
	(e) staff costs	(3,727)	(8,698)
	(f) administration and corporate costs	(978)	(2,447)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	4	8
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	1,791
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(2,946)**	**(6,282)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(27)	(27)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	(1,583)	(2,870)

+ See chapter 19 of the ASX Listing Rules for defined terms.

Consolidated statement of cash flows		Current quarter $A'000	Year to date (6 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(1,610)**	**(2,897)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	42,503	42,503
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(2,200)	(2,200)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	(250)	(351)
3.10	**Net cash from / (used in) financing activities**	**40,053**	**39,952**

Item 3.9: Cash outflows relate to the recognition of costs under AASB 16 Leases for the Group's premises leases, as well as a temporary timing difference in relation to GST on capital raising costs.

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	15,390	19,681
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,946)	(6,282)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (6 months) $A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(1,610)	(2,877)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	40,053	39,952
4.5	Effect of movement in exchange rates on cash held	(80)	333
4.6	**Cash and cash equivalents at end of period**	**50,807**	**50,807**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	21,755	5,561
5.2	Call deposits	29,052	9,829
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**50,807**	**15,390**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	68
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Item 6.1: Payments to Directors consist of the portion Non-Executive Directors' fees paid as cash and superannuation. At 31 December 2021, there were $70,000 in Directors' fees accrued and unpaid related to equity-based remuneration and superannuation.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(2,946)
8.2	Cash and cash equivalents at quarter end (item 4.6)	50,804
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	50,804
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	17

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: .....

Authorised by: .....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.